Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases

Authors

Marco M. Custodio
Jennifer Sparks, Marshall UniversityFollow
Timothy E. Long, Marshall UniversityFollow

Document Type

Article

Publication Date

6-2022

Abstract

This article reviews preclinical and clinical studies on the repurposed use of disulfiram (Antabuse) as an antimicrobial agent. Preclinical research covered on the alcohol sobriety aid includes uses as an anti-MRSA agent, a carbapenamase inhibitor, antifungal drug for candidiasis, and treatment for parasitic diseases due to protozoa (e.g., giardiasis, leishmaniasis, malaria) and helminthes (e.g., schistosomiasis, trichuriasis). Past, current, and pending clinical studies on di_sulfiram as a post-Lyme disease syndrome (PTLDS) therapy, an HIV latency reversal agent, and intervention for COVID-19 infections are also reviewed.

Comments

The version of record is available from the publisher at https://doi.org/10.2174/2211352520666220104104747. Copyright © 2021 Bentham Science.

Recommended Citation

Custodio, M.M., Sparks, J. and Long, T.E., 2022. Disulfiram: A repurposed drug in preclinical and clinical development for the treatment of infectious diseases. Anti-Infective Agents, 20(3), pp.34-45.